Good morning. Ladies and gentlemen, thank you for standing by for Cigna's Fourth Quarter 2019 Results Review. At this time, all callers are in a listen-only mode. We will conduct a question-and-answer session later during the conference and review procedures on how to enter queue to ask question at that time. [Operator Instructions] As a reminder, ladies and gentlemen this conference including the Q&A session is being recorded. We will begin by turning the conference over to Mr. Will McDowell. Please go ahead, Mr. McDowell.

Good morning, everyone and thank you for joining today's call. I’m Will McDowell, Vice President of Investor Relations. With me this morning are David Cordani, our President and Chief Executive Officer; and Eric Palmer, Cigna's Chief Financial Officer. In our remarks today, David and Eric will cover a number of topics including Cigna's full year 2019 financial results, as well as our financial outlook for 2020. As noted in our earnings release when describing our financial results, Cigna uses certain financial measures, adjusted income from operations and adjusted revenues which are not determined in accordance with Accounting Principles Generally Accepted in the United States otherwise known as GAAP. A reconciliation of these measures to the most directly comparable GAAP measures, shareholders net income, and total revenues respectively is contained in today's earnings release which is posted in the Investor Relations section of cigna.com. We use the term labeled Adjusted Income from Operations and Earnings per Share on this same basis as our principle measures of financial performance. I will remind you that as previously disclosed we exclude contributions from transitioning clients from adjusted income from operations, and adjusted revenue. In our remarks today, we will be making some Forward-Looking Statements, including statements regarding our outlook for 2020 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC. Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. Regarding our results, in the fourth quarter we recorded an after tax special item charge of $116 million or $0.31 per share for…

Thanks Will and good morning, everyone. Thank you for joining our call today. In 2019, we delivered consolidated adjusted revenue of $140 billion and grew earnings per share by 20% to $17.05. As a result, we exceeded the guidance that we'd already raised each quarter during 2019 for revenue, earnings and EPS as well as cash flow from operations. Today I'll comment on how we delivered these exceptionally strong results and on the contributions made by each of our four growth platforms led by Health Services and Integrated Medical segments. I'll also discuss how we are positioned to drive attractive growth in 2020 and achieve our 2021 EPS target of $20 to $21 per share. Finally, I'll highlight a key point of differentiation and a driver of future growth, our focus on being the undisputed partner of choice in health care. Following my comments, Eric will share more details about our full year 2019 financial results and 2020 outlook, and then we'll take your questions. Let's dive in. At our Investor Day last year, we committed to building on a decade long track record of delivering industry leading cost trends, consistent growth, and effective capital stewardship. In 2019, we delivered on each of these commitments. While remaining focused on our customers and patients, we executed well across each of our businesses, deepened our customer relationships and achieved our integration priorities. Together this fueled our outstanding performance. In Health Services, we delivered market leading customer and client retention including 97% retention for the 2020 selling season and continued strong organic growth in prescriptions. In commercial, we again delivered industry leading medical cost trend and grew our commercial medical customers for the 10th consecutive year, led by another year of double digit growth in the select segment. And in a government business,…

Thanks, David. Good morning, everyone. In my remarks today, I'll review Cigna's 2019 results and provide our outlook for 2020. Key consolidated financial highlights for 2019 include adjusted revenue of $140 billion, earnings of $6.5 billion after tax, earnings per share growth of 20% to $17.05 and operating cash flows more than doubled this year to $9.5 billion. These results reflect strong consistent execution across our businesses throughout 2019. Regarding our segments, I'll first comment on Health Services. Full year 2019 revenues were $96.4 billion and pre-tax earnings were $5.1 billion. Results for 2019 reflect organic growth, with outstanding client retention and the addition of 2.7 million pharmacy customers, strong volumes with 1.22 billion adjusted pharmacy scripts fulfilled and growth in specialty pharmacy. Overall, Health Services performed well in 2019 with results in line with our expectations and reflecting significant progress across our integration activities. Turning to Integrated Medical, 2019 revenues grew 11% to $36.5 billion driven by commercial customer growth and expansion of specialty relationships, premium growth reflecting underlying cost trends, and the inclusion of the Express Scripts Medicare Part D business. We organically grew our global medical customer base to 17.1 million lives. In 2019, we once again delivered double digit organic customer growth in our select segment with continued enrollment gains in middle market. Full year earnings grew 9% to $3.8 billion reflecting growth in medical customers and specialty relationships, strong operating expense discipline, and continued effective medical cost management. Turning to medical cost, for our total US commercial book of business, full year medical cost trend for 2019 was approximately 4%, which marks the seventh consecutive year Cigna has delivered an industry leading result. Our full year 2019 total medical care ratio or MCR was 80.8%, finishing the year at the low end of our guidance…

Thank you. [Operator Instructions] Our first question is from Justin Lake with Wolfe Research. Mr. Lake, your line is open.

Thanks. Good morning. I wanted to ask a quick numbers question and then a little bit about the capital deployment. So first, just in terms of the group disability sale on numbers. I know you have it in there. Just want to understand how you keep – you deploy capital that you receive to keep this earnings neutral for 2020. Wouldn't the company have to begin buying back stock early or doing ASR given the earnings of go away at a moment in time, and yet the share – the capital deployment might take time.

Justin it's Eric, thanks for the question on that. So just to step back, so for the group disability and life transaction, as we noted, in December, we entered into that agreement, we expect $5.3 billion of after tax proceeds, and we're on track for that to close in the third quarter. Since the $5.3 billion first will be incremental to operating cash flow for the year. We've got flexibility in terms of the timing of how we deploy things and how we deploy capital for the year. Our primary focus is on achieving our debt to capitalization ratio of below 40% by the end of the year and we've got flexibility beyond that and throughout the year to begin to what to do share repurchase and such. We haven't provided any specific guidance in terms of the exact timing of the share repurchase, but we do have flexibility to get started on that even as advanced with the close.

Okay, but will it be earnings neutral through the year, the combination of anything to disability and the capital deployment?

That's our expectation, and that's the guidance that we provided back when we announced the transaction.

Okay, and then if I could just ask a question about the Prime relationship. Congratulations on that obviously. Wanted to understand two things, one, in terms of the relationship itself, it's somewhat narrow in focus, but sounds like it could expand over time. How do you kind of look at the risk versus opportunity to risk being that some of your existing Express Scripts customers we have a much broader relationship, move to Prime and therefore could be somewhat dilutive versus the opportunities to work with these blues and potentially expand that partnership and kind of offset some of that risk.

Justin, good morning, it's David. First and foremost, let me just re-underscore how pleased we are to have entered that relationship. The validation of our deep commitment to servicing health plans, partnering with health plans and growing those relationships. Two, your ability to retain any relationship be a commercial health one otherwise is based on a couple of basic tenets. A, are we able to drive partnership and alignment; B, deliver differentiated value; C, innovate together? We're committed to doing so. And actually we view the opposite of the maybe risk that you identified. This further broadens our reach and our opportunity to serve more lives, both individual customers and patients and a broader portfolio of health plans as we go forward. So we're delighted by securing this and we look forward to beginning to serve that relationship in the second quarter of this year.

Thanks for the color.

Thank you for the question. Our next question is from Kevin Fischbeck with Bank of America. Your line is open, sir.

Okay, great. Thanks. Actually it's a quick numbers question. First two, it sounds like you're saying that the guidance basically is similar to what you were saying with Q3, but you've got another $0.05 drag from this being removed in 2021. Do I just have that right that that's the main change versus Q3 initial outlook?

Kevin its Eric, really two small things to think about there, the incremental drag of a few cents that you noted and we have the benefit of a few cents’ pickup because of the lower share count as we completed repurchase from the time period. Those are the two differences.

Okay, and then the question being, I think that when you guys provided initial membership guidance at the beginning of this year, that was kind of a little bit disappointing. And I guess it's clear now that some of its individual, some of its Medicaid, but you in your presentation have long-term commercial top line growth of 8% to 10%, which is a higher number than I think most people think about as far as commercial growth. How much of that is able to be driven by just growth in the selected middle market accounts? Or do you need to be starting to grow national accounts and individual to kind of achieve that over the long term? And how do you – if so, how do you turn that around?

Kevin its Eric, I'll start on that. First of all, those targets are very consistent with the results we've driven in the commercial markets for a number of years now. And I think the growth in that – the brinks that we target in that business is being driven by really three things. The first category would be around continued customer growth as we continue to grow in the select middle market segments. We've got a lot of opportunity to continue to grow in those segments. The next one, I'd say would be on deepening our existing client’s relationships. So as we work to identify new solutions and deepen our existing solutions in terms of new product sales and again other programs and services. And then the third category I think about would be around, working to innovate and to deliver new solutions more broadly. But again, that's the recipe that we've used for a number of years now. And we see a lot of opportunity to continue on that track in the commercial market.

And you don't need massive account growth per se together or is that part of the growth platform?

Kevin its David, when you think about national accounts, put it back in context, we defined that segment to remind you much more narrow than maybe the market in total. So for Integrated Medical, its commercial employers, 5000 or more employees that are multi-state. Based on that definition and our strategy we view that marketplace as a flat to somewhat shrinking marketplace based on our strategy within Integrated Medical. Now, Eric's point two and point three reinforce how we continue to actually grow and deepen relationships with national accounts. Even today, we're able to successfully do that. And then lastly, we're quite excited about is adding to that more broadly off of our Health Services platform, the ability to offer broader coordinated services. So we could see deepening of relationships and broadening of relationships with the national accounts, even with the medical membership performance that you're making reference to. And over time, we see the ability to even further accelerate that by leveraging our Health Services portfolio. So that will be a net contributor as well.

Thank you for your question. [Operator Instructions] Our next question comes from Dave Windley with Jefferies. Your line is open, sir. Mr. Windley, are you perhaps on mute?

Sorry. Thank you. I was on mute. Sorry about that. Thanks for taking my question on Medicare Advantage. As you look at double digit growth trajectory here and I think that's your expectation for multiple years. That larger cohorts can sometimes come in and put a little pressure on margin. I'm wondering what your expectations are around that and what kind of platform and resources you have in place to onboard risk or risk assess and get new Medicare Advantage members into programs to mitigate any initial margin pressure.

Good morning, it's David. First and foremost, we're really pleased with the start to 2020. As we indicated in 2019, we expect to grow this platform 10% to 15% and we're on track to do 13 to 16. Just back to remind me of some of the context we're well positioned today in 2021. Our Stars rating picks up yet further to 87% of our lives enforced are greater plans. And our net promoter score is tracking yet tad over 70 across our broad portfolio. So our ability to grow both in markets on platforms, net new geographies being adjacent counties and new markets are opening and broadening our PPO platform will feel this and drive it on a go forward basis. Clearly the rate and pace of that growth may put a little margin pressure and draw us toward the low end of our margin range or at times, maybe a tad below that. We'll balance that in our portfolios. We continue to invest as we are today. But we like the growth outlook, we like to aggregate margin profile and we like to sustainability. The last sub note maybe have there in terms of the coding and otherwise, our value based provider relationships and our high engagement programs are well positioned to coordinate the care of the services et cetera as reinforced by the stars rating and as reinforced by our overall performance. So we feel good about the outlook for this year and the trajectory going forward.

Thank you.

Thank you for your question. Our next question is from Steve Tanal with Goldman Sachs. Your line is open, sir.

So I guess one on Oscar. This sounds like a very interesting partnership, but trying to understand what elements of their business are difficult or costly for Cigna to build their offer independently. So just trying to really understand what are the functions each of the companies will do in the context of the partnership. And maybe that's it for me.

Steve thanks, it's David. So stepping back, as I noted in my prepared remarks. First, at a philosophical level, we view that the notion of partnering and beyond partnering, striving to be the undisputed partner choice is a competitive advantage and something we want to build on. Why? It accelerates pace of innovation, it accelerates value creation, whether it be around affordability, predictability, simplicity, it could broaden speed and absolute reach within the marketplace. Oscar is a wonderful example of that. And if you take it up to the macro level, you'll recall that Cigna has historically not participated in the smallest end of the employer marketplace, be it under 50 or under 100, depending on where the regulatory lines are drawn from that standpoint. Two, we believe that's an underserved marketplace with less choice and less leverage of some of the most innovative solutions, not at the core of your question. When you're open minded to partnering, you could have both focused and acceleration in this case by leveraging Oscar's phenomenal technological infrastructure, digital first infrastructure and information flow infrastructure, which is similar to our philosophy, but we just apply it up market and select the middle and national. And this is a case where we're philosophically aligned, but the durable infrastructure is there to serve the unique needs of the small employers and then we're able to port over our value based network configurations, our high performing engagement, clinical behavioral pharmacy capabilities to make one plus one equal a lot more than two. So we're excited about that. And as I noted in my prepared remarks, we're staged to open up four markets to the latter part of this year, and then fuel some growth.

Thank you for your question. Our next question is from AJ Rice with Credit Suisse. Your line is open, sir.

Hi, everybody, just maybe ask about the 2020 bottom on and 2021 bottom line ranges that you have, two parts to it. First, Eric made some comments about divisional level seasonality this year and how we might think about that. I know some of your peers have made a bigger deal about the first quarter and the impact of Leap Year, perhaps because your businesses diversified. It doesn't mean as much to you, but is there anything you'd like to say about the seasonal pattern relative to a normal year? And when you think about the range itself, I guess my question is, there's a number – you got a number of business lines, you got variability around your capital deployment and cost synergy realization. Is that – is there a couple of things in that range that you see is standing out that would particularly move you either to the high end or the low end of your forecasts, given its $0.60 range and $1 range for this year and next? Or is it just the agglomeration of all these different business lines and it falls out. But I guess I'm just trying to figure out of there a couple things that are big variables in your mind as to where you're going to be say versus the $20 to $21 next year.

Eric. On the item related to the Leap Year and the February having an extra day this year that doesn't move the pattern around a little bit in the Integrated Medical segment, all else equal, that runs the loss ratio up a little bit for the first quarter, it'll normalize out over the course of the year, of course, fully factored into our guidance and such, but that does put a modest amount of pressure on the first quarter that will recover over the balance of the year. Nothing that I would call out is particularly significant. As it relates to the range more broadly, there aren't any big items I'd call out other than just the rate and pace of our spending and our investments in terms of future growth. As you know, we have continued to invest in building the capabilities in the like and spend every year as we get ready for new clients to come on board and things along those lines, so it would be those types of items that I think about more than anything else at this point.

Okay, thanks.

Thank you for your question. Our next question is from Ralph Giacobbe with Citi. Your line is open, sir.

Thanks, good morning. I want to go to interest expense guidance, so it looks like your run rating to 1.6 billion at least as of the fourth quarter. The guidance calls for 1.6 billion of interest costs in 2020 despite the 4.5 billion to 5 billion debt pay down. So is it just timing related? Maybe if you can kind of help reconcile that? And then along those lines, I guess to Justin's first question, so I'm sure – that's your repo, I mean, to the extent that you're doing in an accelerating it early on as an offset to the group disability and life does that mean any upside essentially in the first half of the year essentially is not going to carry through to the EPS line simply because of timing I guess. Thank you.

Ralph its Eric, so on the interest expense, really nothing in particular I'd call out other than it may be looking out to the decimal point a little bit further and the timing throughout the year. Obviously, to the extent we were to extinguish that earlier, the interest expense will go down, but again, our current expectation would be for 1.6 billion as I noted in my prepared remarks. In terms of the timing on the capital deployment, the mechanics are consistent with what I outlined to Justin's question. And we do have flexibility in terms of the timing of which we would deploy or our expectation is that we would fully offset the absence of the group transition by reducing the share count through share repurchase. And we'll approach that as we go through the course of the coming months and quarters yeah.

Thank you for your question. Our next question is from Sarah James with Piper Sandler. Ma'am, your line is open.

Thank you. Looking at the five year Medicare growth strategy, there's a shift to focus on PPO. Wondering what dynamics changed in the market to make PPO more attractive and why not focus on group given your large national account base. Your peers have had good success on retiree accounts. So why is that not a strategy pursuing?

Sarah, good morning, it's David. So first and foremost, I wouldn't view it as a shift. We didn't go from something and away from something to something. So the individual HMO continues to be a bedrock of the platform and in fact is the major driver of our growth in 2020 as an example of that. We start to add the individual PPO platform to a portfolio invested to do so, stood it up and have the arrangements with the database provider community to be able to offer that. So it's expanding choice and building on a successful platform and track record. And as we both enter new markets and expanding counties, we will make our decisions in terms of individual HMO, individual PPO or both on a go forward basis. We just see it as an end, I mean, natural extension of our portfolio. Additionally, to your important point, we view that the employer marketplace is also a very attractive addressable market. And as you know, our national accounts are broad while performing commercial portfolios of employee relationships presents another opportunity for that. And it's on our growth trajectory. We're just very disciplined as it relates to building the momentum. So going from the proven HMO to adding the PPO, expanding geographies and you should expect us over time to come back and talk with you about the very attractive additional growth opportunities that exist in the employer marketplace for us as well.

Thank you.

Thank you for your question. Our next question is from Gary Taylor with JP Morgan. Your line is open, sir.

Hi, good morning. Two quick numbers, questions, the first one is to Eric on the 80 basis point impact on the MLR from the HIF recurring next year. Just wondering, when you derive that, do you just presume that on MA there's no impact because there's no explicit growth up there, but just kind of a yes, no question? My other question was on the PBM, so for next year, you've got like 5% at the midpoint pre-tax growth on like 22% script growth. Obviously, the Prime scripts are coming in at breakeven you've told us. We know that the Optum scripts coming over or lower profitability per script. So when we just think about the core and the organic growth in script, should we have Assume that organic EBITDA margins are similar those new organic scripts are coming in at similar margins and in the sort of dilution and profitability per script is purely being driven by Optum and Prime?

Hey, Gary its Eric. On the first part of your question, the short answer is yes. I think of that as not having a specific impact in terms of the quantification given there's not a way to specifically build that into how you bid for MA. On the second portion of your question, absolutely the answer is yes. The dynamics you outlined are really the biggest pieces here. When you adjust for the Prime volumes, I mean, you adjust for the Cigna transition volumes. I think of the core aside from those items is being consistent.

Great, thank you.

Thank you for your question. Our next question is from Matthew Borsch with BMO Capital Markets. Your line is open, sir.

Thank you. Can I just ask about the commercial market maybe a little bit about what you're seeing from, I guess what you call your select segment in terms of preference to shift alternate funding away from risk? And you got any sense for how that may be affecting the risk pools. I'm asking the question partly why there's another company that spoke to seeing some deterioration in the remaining underwriting risk.

Matthew its David, so specific to the commercial marketplace and I think you're going into the select segment. Recall that we offer choice in that marketplace. The choice is heavily oriented around a well configured integrated value proposition with the medical, the pharmacies, the behavior of the care management programs, et cetera and building choice around funding options. Today, think about from a new standpoint, it's tracking about 50-50. About 50% of a new business we're writing right now is risk about 50% of it is ASO stop loss plus or minus, and that vacillates in any given year, a little bit more of one a little bit more of the other and we're delighted with that. We're delighted to be able to be in position to offer it in that way. I'd also remind you from prior conversations, one of our friends, when you offer that choices, oftentimes you're literally offering that choice side by side. And it's a good validation for the purchaser, in this case, the client of our conviction to the ASO proposition when you're able to put the guarantee cost side by side. But today, think about it, the new business running about 50-50. And I wouldn't describe any difference we're seeing in terms of your terminology from a response standpoint and performance, it's performing really well for us.

Thank you.

Thank you for your question. Our next question is from Josh Raskin with Nephron Research. Your line is open, sir.

Thanks. Good morning. I'm going to ask a little bit about capital deployment and you're talking about getting your debt to cap under 40% by the end of this year, you've got another 5.3 billion of proceeds from disability in life and 7.5 billion available deployable cash next year. You think about adding all these numbers up, and it's approaching 20% of the market cap. And I understand the priorities. But is there a little bit more urgency from a capital deployment perspective rather than sort of sitting on cash that's diluted to returns? Do you think about more aggressive buybacks? Is there a dividend increase things like that, I'm just curious if you're starting to feel a little bit more pressure in terms of that deployment?

Josh its Eric. I appreciate the way you frame that up. Obviously, we're very excited about the capital generation that we've got, the cash flow from operations visibility that we've got for 2020 and into 2021 and that gives us a lot of flexibility. And we've got a really good track record of not to use your word sitting on cash, we will deploy the capital in a way that's effective and aligned with our shareholders interest and such versus just accumulating to be clear, but again, the overall history we've got from a – track record we've got from a effectiveness of capital deployment and managing our capital coupled up with the visibility and flexibility that we've got coming with the capital available for us is an exciting combination. David, I don't know what else to add that on that.

Just to reinforce Josh and I appreciate your question. Recall from the – our strategic positioning, pre combination, aided to buy the combination, et cetera. Our ability to generate a significant amount of operating cash flow is a critical competency and we believe the strategic advantage with $9.5 billion in 2019, at least $7.5 billion in 2020 and at least 8.5 billion in 2021, so quite deliberate as Eric said. We note the importance of that responsibility, not something we take lightly, but our effective capital stewardship responsibility will be clear as we go forward and we have tremendous value creation opportunity in front of us right now.

Thank you for your question. Our next question is from Lance Wilkes with Bernstein. Your line is open, sir.

Great, just had a question on the individual business line and the strategy and appetite in that business going forward. And then maybe also, if you can comment on the SG&A increase in Health Services for the fourth quarter, and maybe what drove that?

Lance, good morning, it's David. I'll take the first question and I'll ask Eric to take the second part of your question. Individual business line, I'm presuming you're referencing the individual exchange. Just to remind everybody the individual exchange marketplace, we took a very focused deliberate posture on that – in that marketplace in 2014 and has stayed steady within that marketplace systematically, but slowly growing our posture. We're in 10 markets today. Think about the positioning of being in 10 markets highly oriented around leveraging our value based provider relationships. And that marketplace has performed pretty darn well in the last couple of years. Going forward we'll monitor the competitive landscape, but we see the ability to continue to grow that reasonably over time with fair returns. Cornerstone to our value proposition though is ensuring that in those states, we go down to sub MSA level and make sure we're building the value proper the offering around our highest performing physician relationships and getting the requisite alignment with the delivery system and thus far that's performed well for us. And we look forward to year in year out making individual decisions of additional market expansion. Eric, I'll ask you to address the SG&A comment.

Yes. Lance its Eric. On the Health Services fourth quarter probably two items to have you think about on that front, one, as we noted throughout both David and my prepared remarks continue to spend to invest in terms of building a new and additional capabilities and such. Additionally, we're spending on facilitating and effectuating the transitions associated with the full reinforcing of the Cigna volumes in the life. The other item, I would just note that we've provided some commentary throughout the year last year around the effect of the transition in client going away since as the volumes that are transitioning clients wound down that added costs back into the core, if you will. And we're well on track to extinguish that as we work through 2020.

Great, thanks.

Thank you for your question. Our next question is from Peter Costa with Wells Fargo Securities. Your line is open, sir.

Thank you. I like to follow up with – on Dave's question earlier about margins in Medicare and particular timing of when that'll start to add to your earnings from a perspective of how are you getting the members that you're getting today? Are they coming electronically? Are you setting up broker networks and can you talk a little bit about the channel and how that's going to evolve going forward? And then also in 20 21 with ESRD patients coming on, how do you expect that to impact your margins in the Medicare business?

Peter its David. First, broadly speaking, just to reiterate, we're really pleased with the positioning we have in our existing MSAs and expanding into new markets are individuality to more platform is the lead offering still and the lead part of the growth chassis, aided by the new market entrees as well as the PPO platform. Specifically to your question of how we go-to-market, think about that as an end proposition, so it's a multi-channel approach relative to captive partnered and otherwise and expect that to continue to expand over time. Specific to the margins, as I mentioned to the prior question, the margins we would expect to be at the lower end of the range that we've put out as a long-term range, as we accelerate our growth trajectory over the near term, potentially taking below that having said that, with a growth we would have earnings growth, that that brings along with it. And finally relative ESRD, as we flagged in the past when asked that question, it will be a smaller impact on our aggregate franchise. We will manage the final ESRD posture, MSA by MSA, benefit offering by benefit offering in alignment with our value based physicians. And we will be well positioned to manage that to the extent the final changes transpired is currently proposed from that standpoint. Net-net taken together attractive growth, even at the lower end of the margin range, we will be experiencing earnings expansion while simultaneously investing for growth going forward.

Thank you.

Thank you for your question. Our next question is from Frank Morgan with RBC Capital Markets. Your line is open, sir.

Thank you, two real quick questions. Any thoughts on last night CMAs proposed rule around 2021 you may rate updates and in any update on the Cigna Anthem litigation. Thanks.

Frank its David. Specific to the rate notice, as you might imagine, we're digesting the detail of a given the magnitude of it. It's the preliminary notice you know the process in terms of getting to the final rate notice. And big picture, I would suggest the aware in macro in line with the aggregation of what that rate notice indicates. And when we think about the posture that rate notice, the expansion of our shores proposition for 2021 will be in good shape for 2021. More to follow, but big picture, our impact is broadly speaking in line with what the rate notice speaks to. And as it relates to the – you asked specifically about the Cigna Anthem litigation that is on course to resolve itself by the end of this calendar month.

Any other color you can hear on that? What gives you confidence it would be wrapped up this month and will that result in a settlement payment?

Probably in specificity relative to litigation other than I would reinforce, we feel very strong about our position relative to our contractual responsibility and contractual ability to collect a break fee and the court is on is on track to resolve that by the end of this calendar month.

Thank you.

Thank you for your question. Our next question is from George Hill with Deutsche Bank. Sir, your line is open.

Good morning, guys. And thanks for taking the question. I guess Dave you talked a lot about the partnership strategy and maybe digging a little bit more into Prime – the Prime deal. I guess, can you talk about the network component of it? And I guess where you guys see the most significant points of operating leverage that deliver through to earnings beyond 2020? Is it more on the rebate side or is it more on the network side? And kind of can you talk a little bit about the strength that each side brought to the relationship?

Yeah, I'm not going to go through the micro pieces of the components of the relationship, but I'd rather just reframe what we're trying to achieve together. This is a wonderful example of two organizations identifying philosophical alignment and strategic alignment and then pursuing leverage that results in additional value for customers and clients. That's the end of and the net- net of this, which is improved affordability, potentially improved coordinated access and then clinical program leverage on a go forward basis. We will continue to work with Prime in terms of the best ways in which we could add additional value for them. There's 28 million individual relationships that – or customers and members that are within the Prime relationship and we'll be guided by the components that they feel we can create the most value for will make value added suggestions and evolve that over time, all with the objective of creating more value for their members and clients and therefore getting some benefit for Cigna as well over time. So we're delighted with it. It's another validation of our ability to work with other likeminded partners to create mutual value.

Maybe a quick follow up then, how do we think about you guys effectively strengthening a competitor at the margin or kind of enabling their competition against you in the PBM business?

I appreciate the question. We think about it the exact opposite way. It's a dynamic marketplace and those who create the most valuable win, those who try to preserve or regress to control value will lose over time. So big picture, we're more oriented around a perpetual innovation cycle and continue to drive more value. And we like to do that with others and create mutual value. We have a long track record, the legacy of the ESI [ph] has that, the legacy of Cigna has that and we're fueling more of it. So this is an opportunity to create more value for 28 million more customers starting in 2020, and further improve affordability and further improve quality from that standpoint, that's a great outcome. Each organization has to continue to innovate. Each organization has to deliver value and there's ample growth opportunity in front of both organizations going forward and we'll align to mutually identify beneficial opportunities for both organizations to grow. But the cornerstone is innovation and more value delivery. So we view it as upside not downside.

Thank you for your question. Our next question is from Ricky Goldwasser with Morgan Stanley. Your line is open, sir.

Yeah. Hi, good morning. As we start thinking about a 2021 selling season for the PBM business, can you give us some sense of the size of the book that's up for renewal? And also any order? What's the size of the opportunities you're seeing that's up in the market from the other PBMs? And then my second question is on the MA growth guidance, obviously, you came in – the guidance you base in January was ahead of your initial goal that these near term goals, so maybe you can share with us what really resonated in the marketplace and what do you think drove the above expectations, performance or at least it materializing earlier?

Ricky, good morning, its David, specific to the 2021 PBM selling season break that up as new components, health plan relationships, corporate relationships, as we sit here today, they help find relationships as you would expect and draw close your completion sooner given the size, shape and scope of those relationships. They're substantially completed through the renewal cycle and we feel great about the outcome. So that would be the picture I give you for 2021, continued trends from that standpoint. The corporate part of the relationships are getting into full steam right now. We think we're going to have another very good year from that standpoint and our value proposition is resonating very well in the marketplace, specifically relative to our value proposition and some of the new innovations that we put into the marketplace, be it the patient assurance program, be it health connect 360, et cetera. Put a circle around it in aggregate, think about the size of the book moving or up to move about from a normal standpoint. As it relates to Medicare Advantage, pleased that you're calling out the fact that a bit ahead of the market we put down before, remind you we said 10% to 15% on average over time, we said in our first year, we were expected to be at the lower end of the range as we were stepping into that new result. There's no one driver, what moves us to the 13% to 16%, I would call out a bit higher retention. So what we had initially put into our projection our retentions even higher, we love that. And as I noted in my prepared remarks, we're sitting in an MPS right now, just in excess of 70 across the aggregate book of business that we have and the vast majority of our customers in this space are in value based arrangement. So I wouldn't call it anything else. My existing platforms drove the majority of it, our new markets contributed, and we had a bit higher retention rate.

Thank you.

Thank you for your question. Our next question is from Scott Fidel with Stephens. Your line is open, sir.

Hi, guys. Good morning. Question just on hospital volumes and there's been a little bit of debate on whether those have been picking up or not over the course of the year and just interested from your perspective across both the commercial and Medicare books, what you saw in terms of hospital volumes in the fourth quarter and how those trended relative to your expectations.

Hey Scott its Eric. Overall, nothing that I would call out as particularly notable, we finished the year with the trends of above 4%, which is right in the middle of our expectations. So there's nothing that I would call out as a particular change in trajectory in either the commercial or in the government business.

Okay, thanks.

Thank you for your question. Our next question is from Steven Valiquette with Barclays. Your line is open, sir.

All right, great. Thanks and good morning, Dave and Eric. Thanks for taking the question. So I have two just somewhat interrelated questions on pharmacy? And I guess first, are you able to provide a little more color on your drug procurement strategy going forward for the PBM mail order operations? It's from some conjecture that you may be changing one of your buying group relationships. I'm not sure if you able to comment on that or not. And then secondarily in pharmacy for the 3.5% to 4.5% commercial medical cost trend that you're expecting for 2020. Are you able to discuss whether this includes any incremental pharmacy savings and maybe a lower pharmacy trend this year versus prior years, which obviously may be tied to further integration? Thanks.

Good morning, it's David. I'll take the first question and I'll ask Eric to take the second question. We don't get into individual actions we're taking relative to our supply chain or procurement strategy. I would just step back and say we have a broad portfolio of tools, solutions and capabilities. And we're going to continue to dynamically manage those to get the best possible value for existing and prospective customers and clients going forward. Beyond that, we're not going to comment on any individual actions we're taking in the supply chain activity. Eric, could you comment on the trend.

Yeah, Steve on the trend, we've had pharmacy trend in that low to mid-single digits range for some time now, I mean, that would be the expectation we'd have going into 2020 as well. Just to remind you Express Scripts delivered in 2018 a 0.4% commercial trend. We're publishing our Express Scripts client or trends report later this month, and expect another really attractive result there. But to begin, nothing else I would call out.

Thank you for your question. Our last question will be from Charles Rhyee - Cowen. Your line is open.

Yeah. Hey, thanks for squeezing me in here. Maybe I can ask about – you look at the chart here in your presentation. And obviously, over the last 10 years you've really driven your medical cost trend down. And you're guiding 3.5% to 4.5%. If I'm not mistaken, that's sort of same range you gave last year. I know you've talked about trying to get towards CPI, anything in the short-term that might be keeping you in this range. Can you talk about what are the factors that you're seeing that's going to help you to get lower from here and sort of how we should think about the pacing of that? Thanks.

Charles good morning, first to your point, we're delighted with the fact that we have seven years now going into a plus in terms of delivering the lowest medical cost trend in the industry. And our clients and customers benefit from that immediately, especially given the profile of our business highly ASO oriented from that standpoint and will continue to drive exceptional value for our clients and customers. Two, I appreciate you calling out the CPI level goal and objective. A couple of years ago we put forth a strategic objective which said we strive to deliver a level of medical cost trend approximating CPI by 2021. We view that is indicative of a sustainable trend that the system and society could tolerate and manage on a go forward basis and indicative of a responsible trend. I would note that today we feel like we're well on our way to that journey. And I would underscore that with the fact that many of our clients today who have established relationships with us and are leveraging our most advanced consumer engagement, health improvement and value based relationships are benefiting from CPI or better trend from that standpoint. So there's a toolkit we have that will continue to innovate and evolve around how do we get engagement in support of the consumer in the life journey? How do we evolve the precision and speed of the health improvement programs, especially as we continue to expand in the whole person health arena on an accelerated basis with our market leading behavioral health and pharmacy capabilities? And then just further deepening the activation of value based care delivery platforms that we have in the marketplace and we're already able to deliver as I indicated, CPI are better for many of our clients. We're going to see – further expand that in 2020 and beyond. I appreciate your question.

Thank you for your question. I will now turn the conference over to David Cordani for closing remarks.

Thank you. To wrap up, I'd like to highlight just a few key points from today's conversation. First, to remind your Cigna delivered exceptional full year 2019 financial results across our four growth platforms led by Health Services and Integrated Medical segments. We exceeded the guidance we had already raised each quarter for 2019 for revenue, earnings and EPS as well as for cash flow from operations. Looking forward, our 2019 performance gives us considerable momentum for attractive growth in 2020 and beyond. In 2020, we will continue to drive significant growth in customer relationships, revenue, earnings, EPS, as well as continued strong operating cash flow. We are on track to complete our integration activities associated with our combination with Express Scripts over the next year. We expect to close the sale of our group disability life business to New York Life in the third quarter. We're on track to return our balance sheet to normalized levels and debt and be in a position to provide exceptional strategic financial flexibility moving forward, just as we committed to when we announced our combination two years ago. And we're well positioned to drive attractive growth beyond 2020 and on track to deliver our 2021 EPS target of $20 to $21 per share. We thank you for joining our call today and we look forward to our future conversations.

Ladies and gentlemen, this concludes Cigna's fourth quarter 2019 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing 800-867-1930 or 203-369-3371, no pass code is required. Thank you for participating. We will now disconnect.